POOLBEG PHARMA

AIM: POLB

Poolbeg Pharma

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs.

Our high value programmes target areas including cancer immunotherapy-induced Cytokine release Syndrome (CRS) and metabolic conditions, such as obesity with our oral encapsulated GLP-1 programme. These programmes have multiple near-term value inflection points – positioned well for partnering.

Investment Case

1. Highly experienced team
2. High value programmes
3. Near-term value inflection points

Highly Experienced Team

Proven track record of building successful life science companies and generating shareholder returns

Cathal Friel
Executive Chairman

hVIVO (formerly Open Orphan plc) · AMRYT PHARMA · Raglan Capital

Jeremy Skillington PhD
Chief Executive Officer

INFLAZOME · ETHRIS · Genentech (A Member of the Roche Group)

Ian O'Connell
Chief Financial Officer

hVIVO (formerly Open Orphan plc) · AMRYT PHARMA · Deloitte.

David Allmond
Chief Business Officer

AMRYT PHARMA · Celgene · AMGEN

John McEvoy
SVP, Chief Legal Officer

AMRYT PHARMA · AC · HERBERT SMITH FREEHILLS

Laura Maher
VP Clinical Operations

AMRYT PHARMA · prothena · EORTC (The future of cancer therapy)

High Value Programmes

Product	Modality	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Upcoming Milestones
POLB 001	p38 MAPK inhibitor	Cancer immunotherapy-induced CRS*	Phase 2 ready				▪ Proposed Phase 2a anticipated to start later this year ▪ Phase 2a topline data expected 2026
Oral Encapsulated GLP-1	GLP-1R agonist	Obesity and diabetes		AnaBio Technologies LTD.			▪ POC trial expected to start within the coming months ▪ Topline POC data expected 2026
AI Programmes	Novel drug discovery	Influenza		CytoReason			▪ Potential partnership
		RSV		ONE THREE BIOTECH			▪ Potential partnership

*Further life cycle opportunities, including severe influenza

POLB 001

Potential to enable broader, safer delivery of cancer immunotherapies in an outpatient setting

Cytokine Release Syndrome (CRS)
A severe, potentially life-threatening side effect of cancer immunotherapies

Effective prophylaxis represents a >$10B market opportunity[4]
May enable broader, safer delivery of cancer immunotherapies in outpatient setting

>70%[1] of patients experience CRS
on certain CAR T / bispecific antibody therapies and are restricted to specialist cancer centers

No approved therapies for prevention
Approved options for CRS management (tocilizumab) **have not adequately* prevented** Grade 2+ CRS in clinical trials

1. Rate from Summary of Product Characteristics (SmPCs) for Yescarta, Tecartus, Abecma, Kymriah, Carvykti, Breyanzi, Elrexfio, Columvi, Epkinly, Tecvayli and Talvey; **2.** Datamonitor Healthcare. Forecast: Diffuse Large B-Cell Lymphoma and Multiple Myeloma, 2023; **3.** Abramson JS et al. Blood Adv. 2021 Mar 23;5(6):1695-1705. *In this context, *adequately* is defined as both not completely preventing grade 2+ CRS and potentially sufficient to support active clinical development towards a regulatory approval of a medicine. Grade 2 CRS is defined as described by Lee et al, Biol Blood Marrow Transplant . 2019 Apr;25(4):625-638. janssenscience.com & doi.org/10.1182/blood-2022-159381; **4.** Independent research by Decisive Consulting Limited. https://teamdecisive.com/meet-the-team

From concept to validated preclinical data in 12 months; Phase 2 ready in just 24 months

POLB 001

- Selective p38 MAPK inhibitor
- Oral drug
- Selectively targets excessive inflammation without immunosuppression
- Strong patent portfolio
- Potential for Orphan Drug Designation

Strong Preclinical & Clinical Data

- Phase 2 ready – key value inflection point
- Effectively prevented CRS in humanised mouse model*
- Potent TNF-α and IL-6 inhibition shown in preclinical and clinical trials
- Potent reduction of a range of other inflammatory mediators
- Excellent safety & tolerability profile

* There was no significant or meaningful difference between POLB 001 High dose group and no CRS control group at all timepoints. CRS clinical score is a symptomatic measurement of animal behaviour and appearance
CRS: Cytokine release Syndrome; MAPK: Mitogen Activated Protein Kinase; TNF: Tumour necrosis factor; IL-6: Interleukin-6

Oral GLP-1 Programme Targeting Growing Obesity Market

Preparing a proof-of-concept clinical trial expected to commence in the coming months

US$347B
Economic impact of obesity on US businesses & employees 2023[1]

US$150B
GLP-1R agonist market projection by 2031[2]

Shortcomings of Existing Options

c.99% **API wasted** in current oral options[4]

>45% Patients **discontinue** GLP-1s within 1 year[5]

64% Patients cite **Nausea** for discontinuation[6]

45% Patients cite **Vomiting** for discontinuation[6]

56% Discontinuations would **prefer oral** alternatives[6]

1. Global Data, Assessing the Economic Impact of Obesity and Overweight on Employers, Feb 2024. 2. The Economist, March 2023. 3. Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 prepandemic data files development of files and prevalence estimates for selected health outcomes. Natl Health Stat Report. 2021;158.

Artificial Intelligence Programmes

Actively discussing the exciting outputs from our AI-led programmes with prospective partners

CytoReason

Novel influenza drug targets successfully identified and prioritised

CytoReason's Partners

Pfizer · Roche · sanofi · MERCK

"Human challenge data is extremely rare, and the number of such datasets is limited. None of them have the same richness as this dataset"
Prof Shai Shen-Orr, Co-Founder & Chief Scientist

ONETHREE BIOTECH

Successfully identified drugs with potential to combat RSV with existing clinical data in other indications

OneThree Biotech's Partners

AstraZeneca · Boehringer Ingelheim · LEO · Stanford University

"One thing I was excited about was the uniqueness and quality of the data. AI is only as powerful as the data you bring in"
Neel Madhukar, PhD, CEO

Sign up for RNS alerts

www.PoolbegPharma.com

IR@PoolbegPharma.com